Graticule Asia Macro Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Graticule Asia Macro Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-32,700	Closed	-$2M	–	81
2017 Q3	$2M	Buy	+32,700	New	+$1.73M	0.09%	81
2016 Q2	–	Sell	-92,991	Closed	-$3.68M	–	76
2016 Q1	$3.68M	Sell	92,991 -1,594	-2%	-$63.3K	0.29%	60
2015 Q4	$5.35M	Sell	94,585 -11,915	-11%	-$606K	0.87%	29
2015 Q3	$4.24M	Buy	+106,500	New	+$5.15M	0.49%	37
2015 Q2	–	Sell	-26,000	Closed	-$1.03M	–	100
2015 Q1	$1.03M	Buy	+26,000	New	+$930K	0.14%	42

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Graticule Asia Macro Advisors's NBIX Position: Q4 2017 in Review

Graticule Asia Macro Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2017, closing a stake of 32,700 shares — an estimated $2M sold.

Graticule Asia Macro Advisors first reported a position in NBIX in Q1 2015 and held it in 5 quarters. The position peaked at $5.35M in Q4 2015. 267 funds tracked by Wall St. Rank hold NBIX as of Q4 2017.

Graticule Asia Macro Advisors reported no remaining Neurocrine Biosciences position as of Q4 2017 after selling out during the quarter.
Graticule Asia Macro Advisors sold 32,700 Neurocrine Biosciences shares in Q4 2017, an estimated $2M.
Graticule Asia Macro Advisors first reported a position in Neurocrine Biosciences in Q1 2015 and held it in 5 quarters.
Graticule Asia Macro Advisors's Neurocrine Biosciences position peaked at $5.35M in Q4 2015.
267 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2017.

Based on Graticule Asia Macro Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.